Co-Authors
This is a "connection" page, showing publications co-authored by John Mascola and Adrian McDermott.
Connection Strength
1.419
-
Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. Cold Spring Harb Perspect Biol. 2018 07 02; 10(7).
Score: 0.194
-
Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci Immunol. 2017 Jul 14; 2(13).
Score: 0.181
-
Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection. PLoS One. 2017; 12(3):e0173577.
Score: 0.177
-
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 09 17; 373(6561):1372-1377.
Score: 0.060
-
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
Score: 0.060
-
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 06 10; 384(23):2259-2261.
Score: 0.059
-
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2021 01 07; 384(1):80-82.
Score: 0.057
-
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 10 15; 383(16):1544-1555.
Score: 0.056
-
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 11 12; 383(20):1920-1931.
Score: 0.056
-
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV. 2019 10; 6(10):e667-e679.
Score: 0.052
-
Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat Immunol. 2019 Jun; 20(6):765.
Score: 0.052
-
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV. 2019 05; 6(5):e297-e306.
Score: 0.051
-
Accumulation of follicular CD8+ T cells in pathogenic SIV infection. J Clin Invest. 2018 05 01; 128(5):2089-2103.
Score: 0.048
-
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018 01; 15(1):e1002493.
Score: 0.047
-
Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. Cell Rep. 2017 Dec 05; 21(10):2992-3002.
Score: 0.047
-
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol. 2017 Oct; 13(10):1115-1122.
Score: 0.046
-
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ Vaccines. 2017; 2:15.
Score: 0.045
-
Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. J Virol. 2017 05 15; 91(10).
Score: 0.045
-
Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Rep. 2017 04 25; 19(4):719-732.
Score: 0.045
-
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Sci Transl Med. 2017 01 18; 9(373).
Score: 0.044